|
1
|
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
|
Ann Oncol
|
2011
|
13.95
|
|
2
|
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
|
Ann Oncol
|
2013
|
9.68
|
|
3
|
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
|
Ann Oncol
|
2009
|
9.18
|
|
4
|
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
|
Lancet
|
2007
|
8.08
|
|
5
|
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
|
Ann Oncol
|
2007
|
7.33
|
|
6
|
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
|
Ann Oncol
|
2005
|
5.41
|
|
7
|
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
|
J Clin Oncol
|
2001
|
5.31
|
|
8
|
Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial.
|
Ann Oncol
|
1992
|
4.41
|
|
9
|
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
|
Lancet
|
2000
|
3.79
|
|
10
|
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer.
|
Br Med J (Clin Res Ed)
|
1986
|
3.52
|
|
11
|
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.
|
Ann Oncol
|
2004
|
3.29
|
|
12
|
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
|
Lancet
|
2008
|
2.91
|
|
13
|
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
|
Ann Oncol
|
2006
|
2.72
|
|
14
|
Changing character of cervical cancer in young women.
|
BMJ
|
1989
|
2.66
|
|
15
|
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
|
J Clin Oncol
|
1989
|
2.57
|
|
16
|
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
|
Ann Oncol
|
2008
|
2.26
|
|
17
|
Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients.
|
Cancer
|
1998
|
2.12
|
|
18
|
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer.
|
J Clin Oncol
|
2001
|
2.05
|
|
19
|
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.
|
Ann Oncol
|
1996
|
2.03
|
|
20
|
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
|
J Clin Oncol
|
1998
|
1.94
|
|
21
|
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
|
J Clin Oncol
|
2000
|
1.92
|
|
22
|
Identifying breast cancer patients at high risk for bone metastases.
|
J Clin Oncol
|
2000
|
1.91
|
|
23
|
Psychosocial predictors of survival in metastatic melanoma.
|
J Clin Oncol
|
1999
|
1.83
|
|
24
|
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
|
J Clin Oncol
|
2000
|
1.81
|
|
25
|
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
|
Lancet
|
2001
|
1.79
|
|
26
|
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
|
J Clin Oncol
|
2003
|
1.75
|
|
27
|
Adjuvant therapy for very young women with breast cancer: need for tailored treatments.
|
J Natl Cancer Inst Monogr
|
2001
|
1.67
|
|
28
|
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
|
Ann Oncol
|
2008
|
1.66
|
|
29
|
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
|
Lancet
|
1994
|
1.64
|
|
30
|
Influence of cellular DNA content on survival in advanced ovarian cancer.
|
Cancer Res
|
1984
|
1.58
|
|
31
|
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
|
Ann Oncol
|
2007
|
1.54
|
|
32
|
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
|
J Clin Oncol
|
2001
|
1.49
|
|
33
|
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
|
Ann Oncol
|
2011
|
1.49
|
|
34
|
Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)
|
Ann Oncol
|
1995
|
1.45
|
|
35
|
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
|
Ann Oncol
|
1996
|
1.41
|
|
36
|
Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
|
Cancer Treat Rep
|
1982
|
1.37
|
|
37
|
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
|
Ann Oncol
|
2005
|
1.35
|
|
38
|
Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
|
J Natl Cancer Inst Monogr
|
2001
|
1.29
|
|
39
|
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
|
Ann Oncol
|
2009
|
1.26
|
|
40
|
Subungual melanoma of the hand.
|
J Hand Surg Am
|
1996
|
1.26
|
|
41
|
Experience with 998 cutaneous melanomas of the head and neck over 30 years.
|
Am J Surg
|
1991
|
1.26
|
|
42
|
Missing quality of life data in cancer clinical trials: serious problems and challenges.
|
Stat Med
|
1998
|
1.22
|
|
43
|
First--select the target: better choice of adjuvant treatments for breast cancer patients.
|
Ann Oncol
|
2006
|
1.21
|
|
44
|
Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.
|
Lancet
|
1996
|
1.21
|
|
45
|
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
|
Br J Cancer
|
2002
|
1.17
|
|
46
|
Clinical relevance of single item quality of life indicators in cancer clinical trials.
|
Br J Cancer
|
2001
|
1.13
|
|
47
|
Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.
|
Ann Oncol
|
1997
|
1.07
|
|
48
|
Psychosocial predictors of survival: metastatic breast cancer.
|
Ann Oncol
|
2000
|
1.07
|
|
49
|
Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study.
|
Ann Oncol
|
1998
|
1.05
|
|
50
|
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
|
Melanoma Res
|
1993
|
1.04
|
|
51
|
Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents.
|
Aust N Z J Med
|
1974
|
1.04
|
|
52
|
Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma.
|
Br J Cancer
|
2000
|
1.02
|
|
53
|
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.
|
Ann Oncol
|
2012
|
1.01
|
|
54
|
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
|
Ann Oncol
|
2011
|
1.00
|
|
55
|
Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
|
Br J Cancer
|
2005
|
0.99
|
|
56
|
Immunopathological comparisons between experimental autoimmune encephalomyelitis and multiple sclerosis.
|
Clin Exp Immunol
|
1973
|
0.99
|
|
57
|
Common bile duct obstruction due to intraluminal metastatic melanoma.
|
Aust N Z J Surg
|
1993
|
0.97
|
|
58
|
Immunological cross-reactivity between basic proteins of myelin and cancer. I. Lymphocyte transformation studies in immunized guinea-pigs.
|
Clin Exp Immunol
|
1975
|
0.95
|
|
59
|
Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
|
Ann Oncol
|
1998
|
0.95
|
|
60
|
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
|
Ann Oncol
|
2007
|
0.94
|
|
61
|
Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: an application of multilevel models.
|
Qual Life Res
|
2000
|
0.93
|
|
62
|
Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.
|
Melanoma Res
|
1996
|
0.92
|
|
63
|
Lymphocytes binding basic protein of myelin; cytophilic serum antibody and effect of adjuvant.
|
Immunology
|
1973
|
0.92
|
|
64
|
Radiotherapy and chemotherapy in high-risk breast cancer.
|
N Engl J Med
|
1998
|
0.91
|
|
65
|
Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
|
Eur J Cancer Clin Oncol
|
1987
|
0.91
|
|
66
|
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
|
Ann Oncol
|
2005
|
0.90
|
|
67
|
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
|
Ann Oncol
|
2011
|
0.90
|
|
68
|
Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
|
Br J Cancer
|
2010
|
0.89
|
|
69
|
Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
|
Lancet
|
1999
|
0.88
|
|
70
|
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.
|
Br J Cancer
|
2004
|
0.88
|
|
71
|
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.
|
Breast
|
2003
|
0.87
|
|
72
|
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
|
Breast Cancer Res Treat
|
2013
|
0.86
|
|
73
|
Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.
|
Stat Med
|
1998
|
0.86
|
|
74
|
Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means?
|
Eur J Cancer
|
1991
|
0.85
|
|
75
|
Plasma carcinoembryonic antigen in an Australian hospital population.
|
Med J Aust
|
1976
|
0.84
|
|
76
|
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
|
Ann Oncol
|
2009
|
0.84
|
|
77
|
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
|
J Clin Oncol
|
1997
|
0.83
|
|
78
|
Radical, modified, and selective neck dissection for cutaneous malignant melanoma.
|
Head Neck
|
1995
|
0.83
|
|
79
|
Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy.
|
ANZ J Surg
|
2001
|
0.83
|
|
80
|
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
|
J Clin Oncol
|
1998
|
0.83
|
|
81
|
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
|
Br J Cancer
|
1998
|
0.83
|
|
82
|
Metastatic melanoma presenting at diagnosis as a testicular mass.
|
Aust N Z J Med
|
1992
|
0.82
|
|
83
|
Taxanes as adjuvant for breast cancer.
|
Lancet
|
2000
|
0.82
|
|
84
|
Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group.
|
Eur J Cancer
|
2000
|
0.82
|
|
85
|
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
|
Br J Cancer
|
2012
|
0.82
|
|
86
|
Growth of human melanoma in nude mice: suppression by T-lymphocytes from the tumor donor: brief communication.
|
J Natl Cancer Inst
|
1977
|
0.81
|
|
87
|
Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
|
Br J Cancer
|
1985
|
0.81
|
|
88
|
Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias.
|
Eur J Cancer
|
2009
|
0.81
|
|
89
|
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
|
Ann Oncol
|
2009
|
0.80
|
|
90
|
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
|
Ann Oncol
|
2008
|
0.80
|
|
91
|
Communications. Encephalitogenic activity of peptides from the smaller basic protein of rat myelin.
|
J Immunol
|
1973
|
0.79
|
|
92
|
A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.79
|
|
93
|
Coping with metastatic melanoma: the last year of life.
|
Psychooncology
|
2000
|
0.79
|
|
94
|
Oral cyclophosphamide for the management of hormone-refractory prostate cancer.
|
Br J Urol
|
1993
|
0.78
|
|
95
|
Subsets within the chemotherapy overview. International Breast Cancer Study Group.
|
Lancet
|
1998
|
0.78
|
|
96
|
Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group.
|
J Clin Oncol
|
1993
|
0.78
|
|
97
|
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
|
Br J Cancer
|
2007
|
0.78
|
|
98
|
Tailoring adjuvant treatments for the individual breast cancer patient.
|
Breast
|
2003
|
0.77
|
|
99
|
Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer.
|
Eur J Cancer Clin Oncol
|
1987
|
0.77
|
|
100
|
Thermal neutron capture therapy: the Japanese-Australian clinical trial for malignant melanoma.
|
Basic Life Sci
|
1989
|
0.77
|
|
101
|
Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate.
|
Cancer Treat Rep
|
1987
|
0.77
|
|
102
|
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
|
Cancer Res
|
1982
|
0.76
|
|
103
|
Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy.
|
J Surg Oncol
|
1983
|
0.76
|
|
104
|
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
|
Cancer Treat Rep
|
1985
|
0.76
|
|
105
|
Elective lymph node dissection.
|
J Am Coll Surg
|
1995
|
0.75
|
|
106
|
Adjuvant treatment for breast cancer: the overview.
|
BMJ
|
1992
|
0.75
|
|
107
|
Changing character of cervical cancer in young women.
|
BMJ
|
1989
|
0.75
|
|
108
|
Ethics of randomized clinical trials.
|
J Clin Oncol
|
1998
|
0.75
|
|
109
|
Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer.
|
Ann Oncol
|
2014
|
0.75
|
|
110
|
Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer.
|
Thorax
|
1985
|
0.75
|
|
111
|
Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma.
|
Cancer Immunol Immunother
|
1982
|
0.75
|
|
112
|
New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?
|
Ann Oncol
|
1998
|
0.75
|
|
113
|
Eosinophilic leukaemoid reaction and interleukin-5 in metastatic melanoma.
|
Med J Aust
|
1998
|
0.75
|
|
114
|
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil.
|
Med Pediatr Oncol
|
1988
|
0.75
|
|
115
|
Treatment of advanced squamous-cell carcinoma of the head and neck with a combination of cisplatin, vinblastine, and bleomycin.
|
Med J Aust
|
1984
|
0.75
|
|
116
|
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
|
J Clin Oncol
|
1984
|
0.75
|
|
117
|
Prolonged remission in recurrent bladder carcinoma after chemotherapy with cisplatin.
|
Med J Aust
|
1981
|
0.75
|
|
118
|
Mitolactol chemotherapy for malignant melanoma: a phase II study.
|
Cancer Treat Rep
|
1984
|
0.75
|
|
119
|
Carcinoembryonic antigen in renal allograft recipients and immunosuppressed renal patients.
|
Aust N Z J Med
|
1977
|
0.75
|
|
120
|
Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma.
|
Cancer Treat Rep
|
1982
|
0.75
|
|
121
|
Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
|
Eur J Cancer Clin Oncol
|
1987
|
0.75
|
|
122
|
Meta AMSA (m-AMSA) in patients with advanced ovarian carcinoma.
|
Aust N Z J Obstet Gynaecol
|
1982
|
0.75
|
|
123
|
Leucocytoclastic vasculitis and skin necrosis following subcutaneous heparin calcium.
|
Aust N Z J Med
|
1982
|
0.75
|
|
124
|
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
|
Eur J Cancer Clin Oncol
|
1986
|
0.75
|
|
125
|
Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
|
Aust N Z J Surg
|
1977
|
0.75
|
|
126
|
The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
|
Aust N Z J Surg
|
1979
|
0.75
|
|
127
|
Phase II study of AMSA in patients with advanced ovarian cancer.
|
Cancer Treat Rep
|
1982
|
0.75
|
|
128
|
Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses.
|
Ann Oncol
|
1992
|
0.75
|
|
129
|
Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma.
|
Eur J Cancer
|
1991
|
0.75
|
|
130
|
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
|
Ann Oncol
|
1994
|
0.75
|
|
131
|
Liver biopsy request form: a diagnostic aid.
|
Med J Aust
|
1973
|
0.75
|
|
132
|
Cancer control in Australia.
|
Med J Aust
|
1998
|
0.75
|